The central aim is to evaluate the effectiveness and safety of MMAE for treating chronic subdural hematoma.
Evaluated treatment efficacy of MMAE
Assessed risk of hematoma recurrence
Analyzed safety profiles of the procedure
MMAE significantly reduces the risk of hematoma recurrence
Improvements noted in patient outcomes after treatment
Safety profile indicates a low incidence of complications
Abstract
Middle meningeal artery embolization (MMAE) is an effective modality for treating CSDH, significantly reducing the risk of hematoma recurrence and progression.